Why Venture Capital Alone Won’t Cut It: How Biotech Startups Can Leverage Federal Grants
To email this article to you, sign up here.
You’ve poured your heart and soul into developing new medical technology, but now you need serious funding to get it off the ground. Venture capital alone often won’t cut it for biotech startups. The good news is “Uncle Sam” wants to help. With the right federal grants, your little startup can raise millions to fund research and clinical trials.
The National Institutes of Health (NIH) is the best place to start your search. They offer over 300 grant programs for biotech and healthcare companies. Sure, the application process can be tedious, but winning an NIH grant is like winning the lottery for an early-stage biotech. If you play your cards right, federal funding could be the fuel that propels your company to the next level.
The Struggle Is Real: Why Biotech Startups Have a Hard Time Raising Capital
Raising money is tough for any startup, but biotech companies have it especially rough. Unlike software startups, you can’t bootstrap your way to an MVP. You need serious capital to fund research, clinical trials, and all the regulatory hurdles.
Venture capital is hard to come by in this sector. Biotech is risky, and timelines are long. It can take over a decade to get a new drug to market, and there’s no guarantee of success. Most VCs want a quicker return on their investment.
Angel investors are wary of the sector for the same reasons. They’re looking for the next big tech unicorn, not a company still in the R&D phase.
Public markets aren’t usually an option either, at least not early on. Biotech IPOs tend to happen further down the road.
That’s why federal funding programs are so critical.
The National Institutes of Health (NIH), United States Department of Agriculture (USDA), National Science Foundation (NSF), and other federal agencies offer various grants for biotech research and development.
The NIH is the largest public funder of biomedical research in the world. In fiscal year 2022, NIH invested most of its $45 billion appropriations in research seeking to enhance life and reduce illness and disability. NIH-funded research has led to breakthroughs and new treatments helping people live longer, healthier lives, and building the research foundation that drives discovery.
These programs have awarded billions of dollars to emerging biotech companies. They’re a lifeline for startups still years away from a marketable product.
If you’re a biotech founder struggling to raise money, don’t lose hope.
While venture capital would be ideal, it’s not your only option. Tap into resources like the NIH, NSF, and SBIR/STTR programs. They were created specifically to support innovative companies like yours. With time, hard work, and a little luck, the funding landscape may open up to you. But for now, federal grants could be your ticket to the next milestone.
Venture Capital Funding Has Its Limits
Venture capital funding is crucial for biotech startups, but it only goes so far. VC investors want to see a return on their investment, and fast. This means the pressure is on for your company to rush products to market, scale up quickly, and generate big profits, like, yesterday.
The problem is, biotech isn’t like building an app. Developing new drugs or medical devices takes a ton of time, money, and there’s no guarantee of success. Many promising treatments never even make it out of the lab.
After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last year’s levels.
The slowdown comes amid a broader pullback in global venture funding. Across all sectors, investment hit its zenith in November and has been cresting downward since. On the exit front, meanwhile, the pace of venture-backed IPOs has slowed to a crawl. (Crunchbase)
While venture capital is crucial, federal grants can fill critical funding gaps, reduce risks, and help ensure the long-term success of your biotech startup. The key is tapping into these opportunities at the earliest stages to leverage as much non-dilutive funding as possible. With NIH grants, the sky’s the limit for how far your innovations can go.
Federal Grants: A Lifeline for Biotech Startups
When venture capital runs dry, federal grants can be a lifeline for biotech startups.
Federal Agencies like the NIH offer various research grants, contracts, and partnerships that can provide significant funding and resources for biotech startups. Many successful companies got their start with the help of NIH funding. These grants are highly competitive, but if you do your homework, craft a compelling application, and get a little lucky, NIH funding can be a game changer for your company.
Find the Right Program
With over 300 grant programs, NIH has something for every stage of research and development.
For early-stage biotechs, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants are good places to start. SBIR\STTR grants provide millions each year to help fund critical early research and development.
The SBIR program alone has awarded over $40 billion to small businesses since 1982. These grants are non-dilutive, meaning you don’t have to give up any ownership in your company to get them.
The application process is tough, but if you get a Phase I award (up to $275,000), it can help fund initial research to determine the viability of an idea. Phase II awards (up to $1,5 million) support expanded R&D, testing, and prototype development. These provide up to $2.5 million over 2–3 years for companies to explore the feasibility of innovative concepts. As you mature, larger “R” grants support clinical research and commercialization.
Build a Winning Proposal
An outstanding proposal demonstrates an innovative, impactful idea; technical and scientific merit; and a clear path to commercialization. Do your research to understand NIH priorities and speak to how your work addresses key challenges. Put together a stellar team and advisory board. And don’t underestimate the power of a well-crafted cover letter to grab reviewers’ interest.
Look for Partners
NIH favors proposals with academic partnerships. Collaborating with research universities gives you access to key expertise, facilities, and patient populations to strengthen your application. Winning NIH grants also gives you credibility that attracts top scientific talent, follow-on private funding, and new industry partners.
While the application process is complex, NIH funding is worth the effort for biotech startups. With long timelines to profitability, these non-dilutive funds can help extend your runway, achieve key milestones, and position you for future success. For many biotechs, NIH grants have been pivotal in transforming exciting ideas into commercial realities. With hard work and the right partners, your startup can be among them.
So there you have it, biotech founders. While venture capital is still an important source of funding, especially for later-stage companies, don’t ignore the opportunities in federal grant programs. They provide a way to get your big ideas off the ground and gain momentum when times are tough. The NIH SBIR and STTR grants are a great place to start. Do your research, find the right programs for your technology, and work with people who know the system. With the right approach, these non-dilutive funds could be what takes your startup to the next level. The money is out there, you just have to go get it!
Interested in applying for federal funding? Schedule a call with me today to learn more about available grants and eligibility criteria. Send a call request at funding@ifundlab.com
